FerdinandosSkoulidisMD

Oncology • Houston, TX

Physician

Join to view full profile

Dr. Skoulidis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Skoulidis' full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

Aristotle University of Thessaloniki School of MedicineClass of 2000

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 2018 - 2026
OK State Medical License 2020 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) Start of enrollment: 2020 Feb 14
Active, not recruiting
Phase 2

Publications & Presentations

PubMed

Receptor tyrosine kinase fusion-mediated resistance to EGFR-TKI in EGFR-mutant NSCLC: a multi-center analysis and literature review.
Yang Xia, Kaiwen Wang, Jing Zhao, Zhaohui Arter, Yongchang Zhang
Journal of Thoracic Oncology. 2024-11-30
1 citations
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2024-11-01
2 citations
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung Cancer.
Haniel A Araujo, Ximo Pechuan-Jorge, Teng Zhou, Minh Truong Do, Xin Hu
Cancer Discovery. 2024-11-01

Lectures

Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell l...
2019 ASCO Annual Meeting - 6/1/2019
Association of STK11/LKB1 mutations with primary resistance to PD-1/PD-L1 axis blockade in PD-L1 positive non-squamous NSCLC.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

Should First-Line Dual Checkpoint Blockade Be Used for NSCLC with Specific Mutations?October 24th, 2024
Dual Immunotherapy plus Chemotherapy Benefits Specific Subset of Patients with Lung CancerOctober 9th, 2024
MD Anderson Research Highlights for July 11, 2024July 11th, 2024
Join now to see all